Periocular smearing type oculentum for treating eye diseases and preparation method of periocular smearing type oculentum

Abstract

The invention relates to a periorbital smearing type oculentum for treating eye diseases and a preparation method of the periorbital smearing type oculentum, and belongs to the technical field of eye treatment. Comprising 10-15 parts of a coptis chinensis extract, 5-10 parts of a scutellaria baicalensis extract, 20-30 parts of a wild chrysanthemum flower extract, 8-12 parts of a selfheal extract, 8-12 parts of a plantain seed extract, 8-12 parts of a safflower extract, 80-100 parts of distilled water, 15-20 parts of an antioxidant, 8-12 parts of a heat-clearing and detoxifying agent, 2-5 parts of a cooling and pain-relieving agent and 14-20 parts of a mixing agent. The antioxidant is prepared from 5 to 10 parts of radix scutellariae and 10 to 15 parts of radix angelicae sinensis. The heat-clearing and detoxifying agent comprises 5-10 parts of bear gall powder and 5-8 parts of selfheal. The cooling and pain relieving agent comprises 2-5 parts of borneol and 2-5 parts of menthol. The mixing agent comprises 10-15 parts of glycerol and 4-6 parts of sodium carboxymethyl cellulose. The essential oil further comprises 2-4 parts of tea tree essential oil and 1-3 parts of abelmoschus manihot essential oil. The traditional Chinese medicine composition can effectively improve eye symptoms, increase tear secretion amount and relieve corneal injury.

Description

Technical Field

[0001] The invention relates to the technical field of eye treatment, and in particular to a peri-ocular smearable eye ointment for treating eye diseases and a preparation method thereof. Background Art

[0002] The full name of ophthalmology is "eye disease specialist", which is a discipline that studies diseases that occur in the visual system, including the eyeball and its associated tissues. Ophthalmology generally studies vitreous and retinal diseases, optometry, glaucoma and optic neuropathy, cataracts and other eye diseases.

[0003] Traditional Chinese medicines for eye diseases currently on the market are widely praised for their small side effects. However, the existing traditional Chinese medicines for eye diseases have the defects of poor absorption effect and short duration of efficacy during use. Summary of the invention

[0004] The purpose of the present invention is to address the problems existing in the background technology and to propose an eye ointment for treating eye diseases which can effectively improve eye symptoms, increase tear secretion and reduce corneal damage, and a preparation method thereof.

[0005] The technical solution of the present invention is a kind of eye ointment for treating eye diseases, which comprises, by weight ratio: 10-15 parts of Coptis chinensis extract, 5-10 parts of Scutellaria baicalensis extract, 20-30 parts of Chrysanthemum indici extract, 8-12 parts of Prunella vulgaris extract, 8-12 parts of Plantago seed extract, 8-12 parts of Carthamus tinctorius extract, 80-100 parts of distilled water, 15-20 parts of antioxidant, 8-12 parts of heat-clearing and detoxifying agent, 2-5 parts of cooling analgesic, and 14-20 parts of a mixture.

[0006] Preferably, the antioxidant includes 5-10 parts of Scutellaria baicalensis and 10-15 parts of Angelica sinensis.

[0007] Preferably, the heat-clearing and detoxifying agent includes 5-10 parts of bear bile powder and 5-8 parts of selfheal.

[0008] Preferably, the cooling analgesic comprises 2-5 parts of borneol and 2-5 parts of menthol.

[0009] Preferably, the mixture includes 10-15 parts of glycerol and 4-6 parts of sodium carboxymethyl cellulose.

[0010] Preferably, the mixture further comprises 2-4 parts of tea tree essential oil and 1-3 parts of hibiscus essential oil.

[0011] A method for preparing an eye ointment for treating eye diseases, which is used to prepare the above-mentioned eye ointment for treating eye diseases, characterized in that the method comprises the following steps: S1. Respectively extract Rhizoma Coptidis, Radix Scutellariae, Flos Chrysanthemi Indici, Herba Prunellae, Semen Plantaginis, Carthamus Tinctorius, Radix Angelicae Sinensis, Bear Bile Powder, Borneolum Syntheticum, Menthol, Camellia Sinensis and Hibiscus Mallow by ethanol reflux extraction, filter, and concentrate under reduced pressure to an extract to obtain extracts of each medicinal material; S2, mixing 10-15 parts of coptis root extract, 5-10 parts of scutellaria root extract, 20-30 parts of wild chrysanthemum extract, 8-12 parts of selfheal extract, 8-12 parts of plantain seed extract, 8-12 parts of safflower extract, 80-100 parts of distilled water, 2-4 parts of tea tree essential oil and 1-3 parts of hibiscus essential oil, and stirring for 1 hour to obtain a drug mixture; S3, take 5-10 parts of Radix Scutellariae and 10-15 parts of Radix Angelicae Sinensis to prepare an antioxidant for later use, take 5-10 parts of bear bile powder and 5-8 parts of Herba Prunellae to prepare a heat-clearing and detoxifying agent for later use, take 2-5 parts of borneol and 2-5 parts of menthol to prepare a cooling analgesic agent for later use; S4, mix glycerol and sodium carboxymethyl cellulose, add 50 parts of distilled water, stir evenly, heat to 80-90°C, and continue stirring to make a uniform matrix; S5, gradually adding the mixture made from the medicinal extracts in step S2 to the solution made in step S4, and stirring continuously, maintaining the temperature at 80-90° C., and stirring for 2 h; S6. After the time is up, turn off the heating, add the antioxidant, heat-clearing and detoxifying agent and cooling analgesic agent in step S3 to the matrix, and continue stirring until the matrix temperature naturally cools to 45-50° C. to obtain a paste; S7, naturally cooling the paste in step S6 to room temperature 15-25°C to obtain an ointment.

[0012] Preferably, in step S4, sodium carboxymethyl cellulose is slowly added to distilled water while stirring to avoid agglomeration, and the sodium carboxymethyl cellulose is stirred until the sodium carboxymethyl cellulose is completely dissolved to form a uniform colloidal solution, and glycerol is gradually added to the above colloidal solution while stirring to ensure that the glycerol and the colloidal solution are fully mixed to obtain a mixed solution.

[0013] Preferably, the mixed solution in step S4 is heated to 80-90° C. and stirred at a constant temperature until a transparent and uniform solution is formed; the heated mixed solution is cooled to room temperature and stirred continuously to prevent the solution from stratifying or precipitating.

[0014] Preferably, in step S4, the consistency of the mixture can be adjusted by adding distilled water during stirring; and the cooled mixture is homogenized.

[0015] Compared with the prior art, the present invention has the following beneficial technical effects: In the present invention, the eye ointment for applying around the eyes shows significant clinical efficacy in treating dry eyes, and can effectively improve eye symptoms, increase tear secretion, and reduce corneal damage. Compared with conventional eye drops available on the market, the eye ointment of the present invention has better therapeutic effect and patient compliance. DETAILED DESCRIPTION

[0016] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, the specific embodiments of the present invention are described in detail below.

[0017] In the following description, many specific details are set forth to facilitate a full understanding of the present invention, but the present invention may also be implemented in other ways different from those described herein, and those skilled in the art may make similar generalizations without violating the connotation of the present invention. Therefore, the present invention is not limited to the specific embodiments disclosed below.

[0018] Secondly, the term "one embodiment" or "embodiment" as used herein refers to a specific feature, structure or characteristic that may be included in at least one implementation of the present invention. The term "in one embodiment" that appears in different places in this specification does not necessarily refer to the same embodiment, nor is it an embodiment that is mutually exclusive with other embodiments, either individually or selectively.

[0019] Secondly, the present invention is described in detail with reference to the schematic diagram. When describing the embodiments of the present invention in detail, for the sake of convenience, the cross-sectional diagrams showing the device structure will not be partially enlarged according to the general scale, and the schematic diagrams are only examples, which should not limit the scope of protection of the present invention. In addition, in actual production, the three-dimensional dimensions of length, width and depth should be included.

[0020] Embodiment 1 The present invention provides an eye ointment for treating eye diseases, which comprises, by weight: 10-15 parts of Coptis chinensis extract, 5-10 parts of Scutellaria baicalensis extract, 20-30 parts of Chrysanthemum indici extract, 8-12 parts of Prunella vulgaris extract, 8-12 parts of Plantago seed extract, 8-12 parts of Carthamus tinctorius extract, 80-100 parts of distilled water, 15-20 parts of antioxidant, 8-12 parts of heat-clearing and detoxifying agent, 2-5 parts of cooling analgesic, and 14-20 parts of a mixture.

[0021] The antioxidant includes 5-10 parts of Radix Scutellariae and 10-15 parts of Radix Angelicae Sinensis. The heat-clearing and detoxifying agent includes 5-10 parts of bear bile powder and 5-8 parts of Herba Prunellae. The cooling and analgesic agent includes 2-5 parts of borneol and 2-5 parts of menthol. The mixture includes 10-15 parts of glycerol and 4-6 parts of sodium carboxymethylcellulose. It also includes 2-4 parts of tea tree essential oil and 1-3 parts of hibiscus essential oil.

[0022] A method for preparing an eye ointment for treating eye diseases comprises the following steps: S1. Respectively extract Rhizoma Coptidis, Radix Scutellariae, Flos Chrysanthemi Indici, Herba Prunellae, Semen Plantaginis, Carthamus Tinctorius, Radix Angelicae Sinensis, Bear Bile Powder, Borneolum Syntheticum, Menthol, Camellia Sinensis and Hibiscus Mallow by ethanol reflux extraction, filter, and concentrate under reduced pressure to an extract to obtain extracts of each medicinal material; S2, mixing 10-15 parts of coptis root extract, 5-10 parts of scutellaria root extract, 20-30 parts of wild chrysanthemum extract, 8-12 parts of selfheal extract, 8-12 parts of plantain seed extract, 8-12 parts of safflower extract, 80-100 parts of distilled water, 2-4 parts of tea tree essential oil and 1-3 parts of hibiscus essential oil, and stirring for 1 hour to obtain a drug mixture; S3, take 5-10 parts of Radix Scutellariae and 10-15 parts of Radix Angelicae Sinensis to prepare an antioxidant for later use, take 5-10 parts of bear bile powder and 5-8 parts of Herba Prunellae to prepare a heat-clearing and detoxifying agent for later use, take 2-5 parts of borneol and 2-5 parts of menthol to prepare a cooling analgesic agent for later use; S4, mix glycerol and sodium carboxymethyl cellulose, add 50 parts of distilled water, stir evenly, heat to 80-90°C, and continue stirring to make a uniform matrix; S5, gradually adding the mixture made from the medicinal extracts in step S2 to the solution made in step S4, and stirring continuously, maintaining the temperature at 80-90° C., and stirring for 2 h; S6. After the time is up, turn off the heating, add the antioxidant, heat-clearing and detoxifying agent and cooling analgesic agent in step S3 to the matrix, and continue stirring until the matrix temperature naturally cools to 45-50° C. to obtain a paste; S7, naturally cooling the paste in step S6 to room temperature 15-25°C to obtain an ointment.

[0023] In this embodiment, ointment A is prepared by taking 10 parts of coptis root extract, 5 parts of scutellaria root extract, 20 parts of wild chrysanthemum extract, 8 parts of selfheal extract, 8 parts of plantain seed extract, 8 parts of safflower extract, 80 parts of distilled water, 5 parts of scutellaria root and 10 parts of angelica root as antioxidants, 5 parts of bear bile powder and 5 parts of selfheal as detoxifying agents, 2 parts of borneol and 2 parts of menthol as cooling analgesics, 10 parts of glycerol and 4 parts of sodium carboxymethyl cellulose as a mixture, 2 parts of tea tree essential oil, and 1 part of hibiscus essential oil; Ointment B, comprising 15 parts of coptis root extract, 10 parts of scutellaria root extract, 30 parts of wild chrysanthemum extract, 12 parts of selfheal extract, 12 parts of plantain seed extract, 12 parts of safflower extract, 100 parts of distilled water, antioxidants including 10 parts of scutellaria root and 15 parts of angelica root, heat-clearing and detoxifying agents including 10 parts of bear bile powder and 8 parts of selfheal, cooling and analgesic agents including 5 parts of borneol and 5 parts of menthol, a mixture of 15 parts of glycerin and 6 parts of sodium carboxymethyl cellulose, 4 parts of tea tree essential oil, and 3 parts of hibiscus essential oil; Ointment C, comprising 12 parts of coptis root extract, 7 parts of scutellaria root extract, 25 parts of wild chrysanthemum extract, 10 parts of selfheal extract, 10 parts of plantain seed extract, 10 parts of safflower extract, 90 parts of distilled water, antioxidants including 6 parts of scutellaria root and 12 parts of angelica root, heat-clearing and detoxifying agents including 7 parts of bear bile powder and 6 parts of selfheal, cooling and analgesic agents including 3 parts of borneol and 3 parts of menthol, a mixture of 12 parts of glycerin and 5 parts of sodium carboxymethyl cellulose, 3 parts of tea tree essential oil, and 2 parts of hibiscus essential oil; Preparation method: Steps S1 to S7 are the same as described above.

[0024] Treatment method: The treatment group used the periocular smear eye ointment C of the present invention, twice a day, applied to the periocular area each time; the control group used commercially available conventional eye drops, 4 times a day, 1 drop each time, for 4 consecutive weeks.

[0025] Observation indicators: ocular symptom score, tear secretion, and corneal fluorescence staining score.

[0026] Clinical Results: The average symptom score of the treatment group was 6.8±1.2 before treatment and dropped to 2.3±0.8 after treatment (P<0.01).

[0027] The average symptom score of the control group was 6.5±1.3 before treatment and dropped to 4.1±1.0 after treatment (P<0.05).

[0028] The symptom improvement in the treatment group was significantly better than that in the control group (P<0.05).

[0029] Schirmer test for tear secretion: The average tear volume in the treatment group was 3.2±1.1 mm before treatment and increased to 8.5±2.3 mm after treatment (P<0.01).

[0030] The average tear volume in the control group was 3.3±1.2 mm before treatment and increased to 5.6±1.8 mm after treatment (P<0.05).

[0031] The increase in tear secretion in the treatment group was significantly higher than that in the control group (P<0.05).

[0032] Corneal fluorescence staining score: The average corneal fluorescence staining score in the treatment group was 2.7±0.6 before treatment and dropped to 0.8±0.3 after treatment (P<0.01).

[0033] The average corneal fluorescence staining score in the control group was 2.6±0.7 before treatment and decreased to 1.5±0.5 after treatment (P<0.05).

[0034] The reduction in corneal fluorescence staining score in the treatment group was significantly greater than that in the control group (P<0.05).

[0035] 120 patients with eye diseases were divided into four groups, 30 in each group. The first group used eye ointment with formula A. The second group used eye ointment with formula B. The third group used eye ointment with formula C. The fourth group used commercially available eye drops as the control group.

[0036] Conclusion: The eye ointment for periorbital application of the present invention shows significant clinical efficacy in treating dry eye, and can effectively improve eye symptoms, increase tear secretion, and reduce corneal damage. Compared with conventional eye drops on the market, the eye ointment of the present invention has better therapeutic effect and patient compliance.

[0037] Among patients with eye diseases, the most common one is myopia. Use it three times a day, and a course of treatment is 20 days.

[0038] 120 volunteers were selected, all of whom were myopic patients with a visual acuity of about 0.5 in both eyes. The three samples were respectively distributed to 40 of them; The 40 people who used ointment A had an average visual acuity of 0.52. After one course of treatment, they were revisited and their visual acuity was restored. After the test, the average visual acuity reached 0.60. After the second course of treatment, they were revisited and their visual acuity was tested. The average visual acuity reached 0.66. After examination, after two courses of treatment, some people had reached 0.8, which was a very good effect for those who had serious visual loss before participating in the experiment, that is, for those with pseudomyopia. For those whose eyes had been around 0.5 for many years, at least 0.12 was restored after two courses of treatment.

[0039] The 40 people who used ointment B had an average visual acuity of 0.51. After one course of treatment, they were revisited and their visual acuity was restored. After the test, the average visual acuity reached 0.59. After the second course of treatment, they were revisited and their visual acuity was tested. The average visual acuity reached 0.65. This sample is also very effective for those with pseudomyopia and has a very large effect on those with qualitative vision.

[0040] The 40 people who used ointment C had an average visual acuity of 0.52. After one course of treatment, they were revisited and their visual acuity was restored. After the test, the average visual acuity reached 0.65. After the second course of treatment, they were revisited and their visual acuity was tested. The average visual acuity reached 0.75. This sample is very effective for pseudomyopia and has a very large effect on people with qualitative vision. After two courses of treatment, the visual acuity of people with qualitative vision has recovered by at least 0.18.

[0041] Embodiment 2 The present invention proposes an eye ointment for treating eye diseases around the eyes. Compared with the first embodiment, in step S4 of the present embodiment, sodium carboxymethyl cellulose is slowly added to distilled water, stirring while adding to avoid caking, stirring until the sodium carboxymethyl cellulose is completely dissolved to form a uniform colloidal solution, and glycerol is gradually added to the above colloidal solution, stirring while adding to ensure that the glycerol and the colloidal solution are fully mixed and uniform to obtain a mixed solution. The mixed solution in step S4 is heated to 80-90°C, and stirred at a constant temperature until a transparent and uniform solution is formed; the heated mixed solution is cooled to room temperature, and stirring is continued during the period to prevent the solution from stratifying or precipitating. In step S4, the consistency of the mixture can be adjusted by adding distilled water during stirring; the cooled mixture is homogenized.

[0042] In this embodiment, when dissolving sodium carboxymethyl cellulose, distilled water should be added slowly and stirred continuously to avoid agglomeration and uneven dissolution. The temperature should be controlled during heating to avoid local overheating that may cause the mixture to deteriorate. Stirring should be continued during cooling to prevent the solution from stratifying or precipitation.

[0043] The above describes the embodiments of the present invention in detail, but the present invention is not limited thereto. Various changes can be made within the knowledge scope of those skilled in the art without departing from the spirit of the present invention.

Claims

1. An eye ointment for treating eye diseases, characterized in that: By weight, including: 10-15 parts of Coptis chinensis extract, 5-10 parts of Scutellaria baicalensis extract, 20-30 parts of Chrysanthemum indici extract, 8-12 parts of Prunella vulgaris extract, 8-12 parts of Plantago seed extract, 8-12 parts of Carthamus tinctorius extract, 80-100 parts of distilled water, 15-20 parts of antioxidant, 8-12 parts of heat-clearing and detoxifying agent, 2-5 parts of cooling analgesic, and 14-20 parts of a mixture.

2. The eye ointment for treating eye diseases according to claim 1, characterized in that: Antioxidants include 5-10 parts of Scutellaria baicalensis and 10-15 parts of Angelica sinensis.

3. The periocular smear eye ointment for treating eye diseases according to claim 2, characterized in that: The heat-clearing and detoxifying agent includes 5-10 parts of bear bile powder and 5-8 parts of selfheal.

4. The eye ointment for treating eye diseases according to claim 3, characterized in that: The cooling analgesic comprises 2-5 parts of borneol and 2-5 parts of menthol.

5. The eye ointment for treating eye diseases according to claim 4, characterized in that: The mixing agent comprises 10-15 parts of glycerol and 4-6 parts of sodium carboxymethyl cellulose.

6. The eye ointment for treating eye diseases according to claim 5, characterized in that: Also includes 2-4 parts of tea tree essential oil and 1-3 parts of hibiscus essential oil.

7. A method for preparing an eye ointment for treating eye diseases, which is used to prepare the eye ointment for treating eye diseases according to claim 9, characterized in that: The method comprises the following steps: S1. Respectively extract Rhizoma Coptidis, Radix Scutellariae, Flos Chrysanthemi Indici, Herba Prunellae, Semen Plantaginis, Carthamus Tinctorius, Radix Angelicae Sinensis, Bear Bile Powder, Borneolum Syntheticum, Menthol, Camellia Sinensis and Hibiscus Mallow by ethanol reflux extraction, filter, and concentrate under reduced pressure to an extract to obtain extracts of each medicinal material; S2, mixing 10-15 parts of coptis root extract, 5-10 parts of scutellaria root extract, 20-30 parts of wild chrysanthemum extract, 8-12 parts of selfheal extract, 8-12 parts of plantain seed extract, 8-12 parts of safflower extract, 80-100 parts of distilled water, 2-4 parts of tea tree essential oil and 1-3 parts of hibiscus essential oil, and stirring for 1 hour to obtain a drug mixture; S3, take 5-10 parts of Radix Scutellariae and 10-15 parts of Radix Angelicae Sinensis to prepare an antioxidant for later use, take 5-10 parts of bear bile powder and 5-8 parts of Herba Prunellae to prepare a heat-clearing and detoxifying agent for later use, take 2-5 parts of borneol and 2-5 parts of menthol to prepare a cooling analgesic agent for later use; S4, mix glycerol and sodium carboxymethyl cellulose, add 50 parts of distilled water, stir evenly, heat to 80-90°C, and continue stirring to make a uniform matrix; S5, gradually adding the mixture made from the medicinal extracts in step S2 to the solution made in step S4, and stirring continuously, maintaining the temperature at 80-90° C., and stirring for 2 h; S6. After the time is up, turn off the heating, add the antioxidant, heat-clearing and detoxifying agent and cooling analgesic agent in step S3 to the matrix, and continue stirring until the matrix temperature naturally cools to 45-50° C. to obtain a paste; S7, naturally cooling the paste in step S6 to room temperature 15-25°C to obtain an ointment.

8. The method for preparing the eye ointment for treating eye diseases according to claim 7, characterized in that: In step S4, sodium carboxymethyl cellulose is slowly added to distilled water while stirring to avoid agglomeration, and the sodium carboxymethyl cellulose is stirred until the sodium carboxymethyl cellulose is completely dissolved to form a uniform colloidal solution. Glycerol is gradually added to the above colloidal solution while stirring to ensure that the glycerol and the colloidal solution are fully mixed to obtain a mixed solution.

9. The method for preparing the eye ointment for treating eye diseases according to claim 8, characterized in that: The mixed solution in step S4 is heated to 80-90° C. and stirred at a constant temperature until a transparent and uniform solution is formed; the heated mixed solution is cooled to room temperature and stirred continuously to prevent the solution from stratification or precipitation.

10. The method for preparing the eye ointment for treating eye diseases according to claim 9, characterized in that: In step S4, the consistency of the mixture can be adjusted by adding distilled water during stirring; and the cooled mixture is homogenized.

Images